Market capitalization | $681.67m |
Enterprise Value | $694.83m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 254.52 |
EV/Sales (TTM) EV/Sales | 2.17 |
P/S ratio (TTM) P/S ratio | 2.13 |
P/B ratio (TTM) P/B ratio | 3.19 |
Revenue growth (TTM) Revenue growth | 23.92% |
Revenue (TTM) Revenue | $320.29m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
7 Analysts have issued a Pharming Group N.V. - ADR forecast:
7 Analysts have issued a Pharming Group N.V. - ADR forecast:
Mar '25 |
+/-
%
|
||
Revenue | 320 320 |
24%
24%
|
|
Gross Profit | 290 290 |
31%
31%
|
|
EBITDA | 19 19 |
266%
266%
|
EBIT (Operating Income) EBIT | 6.27 6.27 |
120%
120%
|
Net Profit | -13 -13 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
Head office | Netherlands |
CEO | Fabrice Chouraqui |
Founded | 1988 |
Website | www.pharming.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.